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428Objective: We sought to compare the relative cost-effectiveness of surgical intervention and stereotactic body
radiation therapy in high risk patients with clinical stage I lung cancer (non–small cell lung cancer).
Methods:Wecompared patients chosen for surgical intervention or SBRT for clinical stage I non–small cell lung
cancer. Propensity score matching was used to adjust estimated treatment hazard ratios for the confounding ef-
fects of age, comorbidity index, and clinical stage. We assumed that Medicare-allowable charges were $15,034
for surgical intervention and $13,964 for stereotactic body radiation therapy. The incremental cost-effectiveness
ratiowas estimated as the cost per life year gained over the patient’s remaining lifetime by using a decisionmodel.
Results: Fifty-seven patients in each arm were selected by means of propensity score matching. Median survival
with surgical intervention was 4.1 years, and 4-year survival was 51.4%. With stereotactic body radiation ther-
apy, median survival was 2.9 years, and 4-year survival was 30.1%. Cause-specific survival was identical be-
tween the 2 groups, and the difference in overall survival was not statistically significant. For decision
modeling, stereotactic body radiation therapy was estimated to have a mean expected survival of 2.94 years
at a cost of $14,153 and mean expected survival with surgical intervention was 3.39 years at a cost of
$17,629, for an incremental cost-effectiveness ratio of $7753.
Conclusions: In our analysis stereotactic body radiation therapy appears to be less costly than surgical interven-
tion in high-risk patients with early stage non–small cell lung cancer. However, surgical intervention appears to
meet the standards for cost-effectiveness because of a longer expected overall survival. Should this advantage
not be confirmed in other studies, the cost-effectiveness decision would be likely to change. Prospective random-
ized studies are necessary to strengthen confidence in these results. (J Thorac Cardiovasc Surg 2012;143:428-36)Optimal treatment for patients with early-stage lung cancer
with significant comorbidities remains a challenging prob-
lem. Surgical resection has been considered the gold stan-
dard for patients with acceptable risk, but patients with
significant comorbidities and compromised lung function
have higher morbidity and mortality after surgical interven-
tion.1 Stereotactic body radiation therapy (SBRT) is in-
creasingly recognized as a favorable option in patients
who are not considered operative candidates for early-
stage lung cancer.2-5 Retrospective studies have compared
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The Journal of Thoracic and Cardiovascular Surgbut there remains equipoise among clinicians treating
high-risk patients with early-stage lung cancer. This has
prompted a cooperative group-sponsored prospective ran-
domized trial comparing the 2 treatments in high-risk pa-
tients that has recently started accruing (American
College of Surgeons Oncology Group Z4099/Radiation
Therapy Oncology Group [RTOG] 1021).
Because resources are limited, it is reasonable to compare
the costs of various treatment options for common diseases,
especially if treatments lead to similar clinical outcomes.
Economic evaluation is a method to examine this tradeoff
between the costs and effects of comparative treatments.8
The effectiveness of treatments is evaluated in terms of sur-
vival (life years) attributable to the treatment or quality-
adjusted life years (QALYs).
SBRT for lung cancer has been the subject of several re-
cent cost-effectiveness analyses.9-11 SBRT has been
compared favorably with conventional external beam
radiation therapy and radiofrequency ablation in these
models, either proving dominant or providing improved
effectiveness at acceptable cost. The comparison of SBRT
with particle therapy (protons and carbon ions) was
inconclusive in terms of cost-effectiveness.11 Surgicalery c February 2012
Abbreviations and Acronyms
ACE ¼ Adult Co-Morbidity Evaluation
DLCO ¼ carbon monoxide diffusion in the lung
FEV1 ¼ forced expiratory volume in 1 second
NSCLC ¼ non–small cell lung cancer
PSM ¼ propensity score matching
QALY ¼ quality-adjusted life year
RTOG ¼ Radiation Therapy Oncology Group
SBRT ¼ stereotactic body radiation therapy
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Streatment for lung cancer has not been the subject of scru-
tiny in cost-effectiveness analyses. The objective of the cur-
rent study was to compare the relative cost-effectiveness of
surgical intervention and SBRT in high-risk patients with
clinical stage I non–small cell lung cancer (NSCLC).
MATERIALS AND METHODS
We constructed a Markov decision model to describe the experience
of persons undergoing surgical intervention or SBRT for clinical stage
I NSCLC. Data for the efficacy of surgical intervention and SBRT
were obtained through a review of medical records of patients treated
with surgical intervention or SBRT for clinical stage I NSCLC staged
based on the results of computed tomographic and positron emission to-
mographic scanning at Washington University in St Louis. All surgical
patients with clinical stage I lung cancer treated between January 1,
2000, and December 31, 2006, and all patients between February 1,
2004, and May 5, 2007, with clinical stage I lung cancer undergoing
treatment with SBRTwere included and analyzed according to a protocol
approved by our institutional review board. Comorbidity scores were re-
corded prospectively by using the Adult Co-Morbidity Evaluation (ACE)
27 scoring system. The ACE-27 is a unique 27-item comorbidity index
developed for patients with cancer that is easy to use and has demon-
strated good ability to define unique prognostic subgroups. Data on pa-
tients’ demographics, history and physical examination results,
evaluation by means of chest computed tomographic scans and fluoro-
deoxyglucose positron emission tomographic scans, operative reports,
and final pathology reports (where available) were obtained from medical
records. Current standard SBRT dosing at our center delivers 54 Gy in 3
fractions over 8 to 14 days, as demonstrated in trials by the RTOG. The
SBRT device used was the Trilogy system (Varian Medical Systems, Inc,
Palo Alto, Calif). This device does not generally require the placement of
fiducial markers.
It is well known that the patients referred to SBRTand surgical interven-
tion in a clinical setting have markedly different expected mortalities. In
our multidisciplinary setting patients are typically seen by a surgeon at di-
agnosis, and a decision is made as to whether surgical intervention can be
safely performed. The vast majority of patients undergoing SBRT had been
refused resection by the surgical team. This did introduce a significant se-
lection bias in the patient population. This selection bias might put the pa-
tients undergoing SBRT at an unmeasurable disadvantage. This made
creating matched cohorts difficult. We attempted to address this using pro-
pensity scoring methods.
Propensity score matching (PSM) was performed between the surgical
intervention and SBRT groups on the basis of ACE-27 scores, age (71.5 vs
71.8 years), and clinical tumor (T) stage (70% T1 vs 68% T1). Statistical
analysis was performed with SPSS 11.0 software for Windows (SPSS, Inc,
Chicago, Ill).6 In the PSM analysis logistic regression was used to estimate
the corresponding scores from the baseline patient covariates. To findThe Journal of Thoracic and Camatched patients from the 2 groups, we adopted a caliper matching ap-
proach. Starting with most constringent radii (0.0005 and 0.001), only
a very small number of surgical patients could be matched because of
the significant comorbidity of patients in the SBRT group. At a caliper ra-
dius of 0.005, 57 patients in each group could be matched.6
According to the recommendation of the Panel on Cost-effectiveness in
Health andMedicine, we based costs on theMedicare-allowable charges.12
Costs for patients undergoing surgical intervention were $15,034 for those
who did not undergo chemotherapy and $24,134 for patients who under-
went chemotherapy. We assumed that surgical mortality resulted in in-
creased charges (Table 1).13-15 The Medicare-allowable charges for
patients undergoing SBRT were $13,964 for uncomplicated patients.
The Markov decision model was constructed by using TreeAge 2009
software (TreeAge Software, Williamsport, Mass) and estimated by using
a microsimulation process.16 Microsimulation refers to a simulation pro-
cess in which simulated participants are assigned characteristics on an in-
dividual basis and pass through the model one at a time, facing probability
nodes as they pass through the model. Each time they reach the probability
node, the occurrence of an event is determined by the result of a probabilis-
tic distribution (akin to the flip of a biased 2-sided coin) to that simulated
individual. Transition probabilities were parameterized as a random vari-
able by using the mean and variance to estimate a b distribution. Survival
estimates were based onKaplan-Meier survival probabilities. Each individ-
ual completes the tree (and all cycles) before another simulated individual
enters the model and the value of each transition probability is resampled.
In our simulation the cohort had 1000 simulated members and was re-
sampled 500 times (for a total of 500,000 trials). This approach allows
the investigator to fully recognize the influence of both individual- and
group-level variation on the study results.
The Markov model is a mathematic representation of an iterative pro-
cess, with a Markov cycle representing the length of the iterative process.2
In this case the iterative process describes the experience of a patient under-
going either surgical intervention or SBRT. In the surgical arm the patient
initially has surgical intervention, and we assume that the operation is suc-
cessful or that she or he dies. If the operation is successful, the tissue is an-
alyzed, and if the NSCLC is stage N0, the patient then cycles through 5
years, during which there is a chance of recurrence or death from other
causes (ie, the same background risk of mortality of the general public).
If the cancer is upstaged to N1 or N2, the patient might receive chemother-
apy. Regardless of whether chemotherapy is given, patients face an in-
creased possibility of recurrence or death over that experienced by
patients at stage N0. If the cancer is staged N2, there is an increased prob-
ability of recurrence and death over that seen in patients with stage N0 or
N1 disease.
Patients undergoing SBRT follow a much simpler path. With SBRT, the
patient faces the possibility of complications and consequent cost. Mortal-
ity for the simulated participants in the SBRT arm was based on that ob-
served in the SBRT study cohort. Because there is no nodal tissue taken
from patients undergoing SBRT, there is no pathological nodal staging of
their disease. Therefore the mortality risk estimated for these cohort mem-
bers is the average of patients who underwent SBRT. There is no parsing of
mortality risk by disease severity as with the surgical group.
The influence of uncertainty on model results was evaluated in 2 ways.
First, we performed 1- and 2-way sensitivity analyses to determine the ef-
fect of our parameter assumptions on the outcome. For this process, the
value of each parameter was varied across the entire relevant range, and
the outcomewas assessed. To test the overall stability of themodel, we con-
ducted probabilistic sensitivity analysis by using the 2-stage Monte Carlo
approach defined above. Cost-effectiveness acceptability graphs17 were
plotted based on the net benefit estimated for each simulation. For this pur-
pose, net benefit is calculated as follows:
ðPatient years lived3Willingness to payÞCost of treatment
¼ Net benefit:rdiovascular Surgery c Volume 143, Number 2 429
TABLE 1. Costs of therapy used in the decision model
Clinical scenario/intervention
Cost
(2010 dollars) Source
Surgical intervention for
early-stage lung cancer
15,034 CMS allowable
Surgical mortality 40,100 CMS allowable
SBRT (3 fractions) 13,964 CMS allowable
Pulmonary complications 11,000 CMS allowable,
Reference24,25
Chemotherapy 9,100 Reference26
CMS, Center for Medicare and Medicaid Services; SBRT, stereotactic body radiation
therapy.
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FIGURE 1. Kaplan-Meier plot of overall survival for the 2 groups: log
rank ¼ 2.692, P ¼ .10. SBRT, Stereotactic body radiation therapy.
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SHere, willingness to pay would be the willingness to pay for a life year
gained. Because there is no known willingness to pay for a life year gained,
we varied this across a wide range of values ($0–$200,000) to determine
what influence this assumption would have on our results.
RESULTS
Of 462 patients undergoing surgical intervention and 76
undergoing SBRT, 114 patients (57 in each arm) were se-
lected by means of propensity matching (Table 2). In the
surgical group operative mortality was 4 (7%) of 57. Me-
dian survival was 4.2 years, and 4-year survival was
51.4% (n ¼ 21). Thirteen of 53 surgical survivors with in-
cidental N1/N2 disease (11 with N1 and 2 with N2 disease)
were eligible for chemotherapy. Of these, 7 patients under-
went chemotherapy. In the SBRT arm there was no
treatment-related mortality, and the rate of major morbidity
was 1.8% (1/57). None of the patients undergoing SBRT re-
ceived chemotherapy. Median survival was 2.9 years, and
4-year survival was 30.1% (n ¼ 12, P ¼ .101). The overall
and cause-specific survival for both groups was not signifi-
cantly different and is depicted in Figures 1 and 2.TABLE 2. Pretreatment and operative characteristics of surgically
treated patients and patients undergoing SBRT for clinical stage I
lung cancer
Variable
Surgical
intervention
(n ¼ 57) SBRT (n ¼ 57)
P
value
Mean age (y)* 71.54  7.9 71.79  10.6 .889
Median age (y) 73 (range, 47–90) 72 (range, 50–94)
Male sex 34 (59.6%) 23 (40%) .039
Clinical T1* 40 (70.2%) 39 (68.4%) .839
FEV1,% predicted
(mean)
0.77 0.50 <.001
DLCO,% predicted
(mean)
0.81 0.50 .01
ACE score 2–3* 36 39 .501
Operation
Lobectomy 46 (80.7%) NA
Sublobar resection 11 (19.3%) NA
ACE, Adult Co-Morbidity Evaluation; DLCO, carbon monoxide diffusion in the lung;
FEV1, forced expiratory volume in 1 second; NA, not applicable; SBRT, stereotactic
body radiation therapy. *Variables considered in propensity matching.
430 The Journal of Thoracic and Cardiovascular SurgThe results of our cost-effectiveness analysis are pre-
sented in Table 3, and the Markov diagram is depicted in
Figure 3. The expected cost of treating patients with surgi-
cal intervention was $17,629, and there was an expected
survival of 3.39 years during the 5-year period evaluated
in modeling. Compared with SBRT, patients treated with
surgical intervention incurred an expected incremental
cost of $3476 but lived an additional 0.45 years, resulting
in an incremental cost-effectiveness ratio of $7753 per ad-
ditional year of survival.1183 50
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FIGURE 2. Kaplan-Meier plot of cause-specific survival for the 2 groups:
log rank ¼ 0.449, P ¼ .50. SBRT, Stereotactic body radiation therapy.
ery c February 2012
TABLE 3. Results of base case cost-effectiveness analysis
Strategy Total cost
Incremental
cost
Total
effectiveness (y)
Incremental
effectiveness (y)
Incremental
cost-effectiveness ratio (cost/y)
SBRT $14,153 2.94
Surgical intervention $17,629 $3476 3.39 0.45 $7753
SBRT, Stereotactic body radiation therapy.
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SThe results of 1-way sensitivity analysis are presented in
Table 4. The cost-effectiveness decision was most sensitive
to the rate of surgical mortality and N2 metastasis. For the
cost-effectiveness decision to change, the rate of surgical
mortality must increase by more than 2-fold from the base
of 7%, and the rate of N2 metastases must increase by
4-fold from the base of 3.5%.
Finally, the result of our probabilistic sensitivity analysis
is shown in the cost-effectiveness acceptability curve in
Figure 4. This figure illustrates the results of our Monte
Carlo simulation by summarizing the proportion of cases
for each of the 500,000 simulated trials for which the indi-
cated treatment option (surgical intervention or SBRT) re-
sulted in the most net benefit at that willingness to pay.
For instance, at a willingness to pay of $72,000 per life
year gained, approximately 85% of the trials resulted in
greater net benefit for surgical intervention than SBRT.
This would imply (given the assumptions of our model)
that a policymaker with a willingness to pay of $72,000
per life year gained would make the correct decision 85%
of the time should she or he choose to have the patient un-
dergo surgical intervention (where ‘‘correct’’ is defined as
generating the most net benefit).
DISCUSSION
The majority of patients in the surgical arm underwent
lobectomy. This is in contrast to some other surgical series
in which authors have used sublobar resections in high-risk
patients.18-21 A comparison between patients undergoing
SBRT and those undergoing sublobar resection would be
a more ideal cohort, but our limited number of patients
undergoing sublobar resection precluded a meaningful
comparison in the current series. This distribution in our
series is likely related to the selection process of
propensity matching, in which lung function is only one
aspect of the comorbidity index. Also, the forced
expiratory volume in 1 second (FEV1) and carbon
monoxide diffusion in the lung (DLCO) percentages in
our surgical patients were higher than those in the
patients in the aforementioned series, as well as those in
the SBRT arm of the current study. Attempts at using
more stringent matching criteria between the 2 groups,
including lung function tests specifically, yielded very
few patients for comparison. The surgical mortality in
our selected high-risk surgical patients was 7%, which is
higher than the 1% to 4% mortality generally reportedThe Journal of Thoracic and Cafor lobectomy.1 Among our low-risk surgical patients,
the mortality was 2.7% (11/405). The 4-year survival in
the 57 surgical patients was 51%. This is slightly lower
than the survival seen in large databases (clinical stage
IA, 50% 5-year survival; clinical stage IB, 43% 5-year
survival)22 and is likely related to the selection of
a higher-risk group for study. The clinical outcomes in
the SBRT cohort were similar to published data for medi-
cally inoperable patients undergoing SBRT, both in terms
of complications and survival.2-4
For the purpose of this study, we used Medicare-
allowable charges as costs where possible. This approach
ensures uniformity of cost data and makes the results as
broadly applicable as possible and has been used by others.9
Medicare-allowable charges vary geographically, but gen-
erally, the direction and degree of change (increase or de-
crease) can be expected to be similar for both treatment
arms. Alternate standardized sources of cost have been
used in other studies.10-12 Although it is meaningful to
use a standardized system of cost estimation for economic
analyses in medicine, charges billed by individual
institutions for the same service vary widely,9 as does the
eventual amount reimbursed by private insurers. There is
also an understandable reluctance on the part of institutions
to share their actual cost and charge information, thus ex-
plaining the lack of this information in published literature.
The cost-effectiveness analysis in the present study was
performed from a payer’s perspective. The payer is defined
as an individual or organization that assumes financial re-
sponsibility for health care services. Alternate approaches
to economic analyses in medicine are to consider the soci-
etal perspective or a combined approach.23,24 The societal
perspective is the broadest possible perspective for an
economic evaluation. It includes all program costs, no
matter who incurs them, and all program consequences,
no matter who experiences them. In the societal
perspective the net cost of an intervention is calculated by
deducting the cost of disease averted and the cost of
productivity losses from the program cost. Thus an
intervention that is more effective and also more costly
from a payer’s perspective is likely to look more attractive
(lower incremental cost-effectiveness ratio) from a societal
perspective when costs averted are deducted from the cost
of the intervention.
We used absolute survival in years for the 2 treatment
arms for the effectiveness data in our study. An alternaterdiovascular Surgery c Volume 143, Number 2 431
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FIGURE 3. Markov model depicting the decisions analysis showing the surgical intervention and stereotactic body radiation therapy (SBRT) arms.
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Sapproach used by several authors is to use QALYs. Any
state of health or disability is assigned a utility on a scale
ranging from 0 (immediate death) to 1 (a state of perfect
health) to calculate QALYs. The outcome of any health432 The Journal of Thoracic and Cardiovascular Surgintervention can then be calculated as the product of the in-
crease in utility that it might cause and the time in years over
which it might be enjoyed. Because our studywas retrospec-
tive, we could not interview patients to assign a utility valueery c February 2012
FIGURE 4. Cost-effectiveness acceptability curve based on the results of
Monte Carlo simulation. At a willingness to pay of $72,000 per life year
gained, approximately 85% of the trials resulted in greater net benefit
for surgical intervention than for stereotactic body radiation therapy
(SBRT).
TABLE 4. Results of 1-way sensitivity analysis
Variable (base case value) Value tested ICER
Surgical mortality (7%) 0% $2583
17% $68,859
20% Surgery dominated/
SBRT dominant
SBRT complications (1.8%) 0% $8341
20% $3337
Probability of chemotherapy
(50% of node positive)
0% $7011
100% $8681
N1 mets (% of total surgeries, 19%) 0% $5665
30% $14,355
N2 mets (% of total surgeries, 3.5%) 0% $7154
15% $62280
The base case values are shown. The values of variables tested in the model are also
shown. The cost-effectiveness decision was most sensitive to the rate of surgical mor-
tality and N2metastasis. ICER, Incremental cost effectiveness ratio;mets, metastases;
SBRT, stereotactic body radiation therapy.
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Sto the absolute survival. Utilities are currently measured by
using different techniques, and the results vary according to
themethod used.25 Thus reliability cannot be assumed, espe-
cially when utilities are measured by using different tech-
niques. This prevented us from using utilities in published
literature for calculating QALYs in our patients. Addition-
ally, because we did not use QALYs in the current study,
we could not state a level of willingness to pay.
Our sensitivity analyses demonstrated that the cost-
effectiveness decision was extremely robust to our model
assumptions. The only parameters that affected the decision
were the rate of surgical mortality and the rate of metastasis.
However, metastases are a function of disease severity and
in this manner affect postoperative mortality and cost of
treatment through the use of chemotherapy. Increased risk
of metastases shortens life expectancy for surgical patients,
but because we do not know the rate of metastases in pa-
tients undergoing SBRT, we could not include this parame-
ter in the SBRTarm of the economic model. The purpose of
sensitivity analyses is to assess the influence of a change in
the true population parameter on the cost-effectiveness de-
cision. If the true rate of N2 metastases in the population
was 15% (rather than 3.5%), mortality would be affected
for patients undergoing SBRT, as well as patients undergo-
ing surgical intervention. If we were to reflect this in our
modeling, mortality in the SBRT arm should be changed
as the N1 and N2 rate is increased in the surgical arm. How-
ever, we lacked evidence on which to base such parameters.
Therefore we took the more conservative approach of af-
fecting only the surgical arm. This makes it likely we are
overstating the importance of N2 metastases in the cost-
effectiveness decision.The Journal of Thoracic and CaOur study has certain limitations. The economic advan-
tage for surgical intervention in this analysis is the result
of longer survival for surgical patients in our retrospective
analysis, and if survival were identical for both groups,
the cost advantage of SBRT would make it the dominant
therapy choice. Our cohort study suffers from the biases
of any retrospective analysis, including selection bias in
treatment allocation. Thus patients undergoing SBRT, de-
spite being matched with the surgical cohort by means of
PSM, had lower performance on pulmonary function tests
and suffered from selection bias and thus suffered from
morbidity that might not have been captured in the propen-
sity matching. The difference in overall survival between
the 2 groups was not statistically significant; however, there
appeared to be a suggestive split in the curves at later time
points favoring surgical patients. However, the nearly iden-
tical cause-specific survival rates between the 2 groups
(Figure 2) indicate that most patients undergoing SBRT
died of causes unrelated to their lung cancer, and the onco-
logic superiority of either treatment arm cannot be assumed.
Additionally, 11% of patients undergoing SBRT received
doses of less than the biological equivalent dose threshold
of 100 Gy10, which has been associated with inferior local
control and overall survival in prior publications.4,26
The surgical patients in our series were from an earlier
timeframe than the patients undergoing SBRT. This partly
stems from the fact that SBRT is a relatively newer intro-
duction to the treatment of lung cancer, and to find compa-
rable patients in the 2 groups, we had to include surgical
patients from a longer time period. This also meant that
all of the surgical patients had undergone a thoracotomy
for resection.
The lack of preoperative surgical staging in the patients
undergoing SBRT is also a limitation of this study. Treat-
ment options were limited in these high-risk patients, andrdiovascular Surgery c Volume 143, Number 2 433
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Sit was often determined that surgical staging would not sig-
nificantly alter the treatment plan. Moreover, modeling al-
ways involves a degree of simplification, and a model
should not be faulted because available data do not meet
the ideal standards of scientific evidence.
The ideal scenario for conducting cost-effectiveness anal-
yses in medicine is when cost and utility data are collected
prospectively in a randomized controlled trial. For the cur-
rent comparison between SBRT and surgical intervention
in the high-risk patient with lung cancer, such a trial is cur-
rently underway (American College of Surgeons Oncology
Group Z4099/RTOG 1021), and a cost-effectiveness analy-
sis is planned. Data collected from this and other, similar
larger population-based studies will further clarify the rela-
tive cost-effectiveness of surgical intervention and SBRT.References
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Dr Alessandro Brunelli (Ancona, Italy). Mr Chairmen, col-
leagues. I have no conflicts of interest to disclose.
Dr Puri, I want to congratulate you and your colleagues from St
Louis for this timely and interesting contribution. As usual, your
group has performed this very accurate analysis in the context of
a nonrandomized observational investigation. SBRT is emerging
as an effective treatment for functionally inoperable NSCLC.
However, you have demonstrated with a decision model that sur-
gical intervention remains cost-effective, even for these high–
risk patients. I have 3 comments and questions, and I will ask
you one at a time.
Although propensity scoring was appropriately applied in an at-
tempt to minimize the selection bias, the 2 groups of patients did
not seem quite well matched. Surgical patients were more fre-
quently male and had higher FEV1 and DLCO values. Also, the
vast majority of surgical patients underwent lobectomy instead
of minor resection. In my opinion SBRT should be best compared
with minor resection instead of lobectomy. Minor resection consti-
tuted only 19% of your surgical series. Have you tried to restrict
the matching analysis only to minor resections? This would prob-
ably improve your matching and probably will influence the out-
come of the decision model.
Dr Puri. Dr Brunelli, that is a very appropriate comment. For
PSM, just to give you a little bit of background, we had about
500 patients in the surgical arm and about 85 patients in the stereo-
tactic radiation arm, which was used as a dataset for abstracting
these 57 patients. At the very outset, we set extremely stringent cri-
teria in terms of comorbidities and lung function tests to match
these patients. We came up with about 28 or 30 patients we could
actually match, therefore about 15 in each arm, which eventually
led us to believe that there was no way that we could keep subse-
quent criteria and come up with a number of patients who could
actually be analyzed.
Therefore we used the caliper matching method; I showed you
a slide in which the caliper radius that was used was 0.005. There-
fore in a caliper matching method, which essentially means at theery c February 2012
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Scenter of the circle, the patients are perfectly matched. Then you
use a radius and draw a circle around that center. All the patients
who fall within that circle are considered well matched by using
the propensity score analysis. Therefore if you increase the radius
of the caliper, a larger number of patients will be well matched by
means of PSM.
When we used extremely stringent radius criteria, we again
came up with about 25 or 30 patients who could be matched.
Therefore we had to gradually make our criteria more lax to
come up with an analyzable number of patients. Thus we do
have, I would say, an unmeasurable bias against the patients under-
going SBRT, but this is the best PSM that we could achieve.
Dr Brunelli. In the construction of the propensity score, you
used the adult comorbidity evaluation score. By the nature of the
patients under analysis and the methodology used to calculate
the overall score, the majority of the patients had an overall score
of 2 or 3, making this parameter less than ideal to discriminate be-
tween high-risk and low-risk patients in this context. Have you
tried to use more individual and more specific parameters, such
as FEV1, DLCO, the presence of coronary artery disease, or body
mass index, along with the ACE score, to improve your propensity
score construction?
Dr Puri. The ACE–27 score is a score that is collected prospec-
tively, and as Dr Brunelli points out, it goes from mild problems
(ie, level I) to moderate (ie, level II) and severe (ie, level III) co-
morbidity, and most of the patients had moderate or severe comor-
bidities that were either level II or level III. Again, whenwe tried to
use the ACE–27 score in addition to using FEV1, the number of
patients we could come up with that could be extremely well
matched was quite small and not analyzable.
Dr Brunelli. Finally, almost 21% of the patients in the surgical
arm turned out to be N-node positive, and 50% of them were sub-
mitted to adjuvant chemotherapy. However, in the decision model
patients undergoing SBRTwere all regarded as having pathologi-
cal stage 1 disease because they had no nodal biopsy. Did some of
these patients undergo chemotherapy in addition to SBRT?We as-
sume that at least an equal proportion of patients undergoing SBRT
would have node-positive disease, at least equal to the surgical pa-
tients. Have you tried to repeat the analysis by adding lymph node
staging and chemotherapy probability nodes in the decision
models also for the SBRT group, assuming the same probability
of the surgical population? Do you have any data from your center
or from the literature of concurrent SBRT and chemotherapy on
which to base this methodological approach?
I thank the Association for the privilege to discuss this excellent
article. Thank you very much.
Dr Puri. Dr Brunelli, with regard to your last point, you are en-
tirely correct in biologically assuming that the incidence of nodal
disease would be expected to be the same in the 57 patients under-
going SBRT as in the surgical patients. None of these patients re-
ceived chemotherapy up front, and therefore they were all treated
with stereotactic radiation. As we accumulated more data on recur-
rences, either nodal, distant, or local, theywere givenmore therapy.
However, we do not have any data for up-front chemotherapy along
with stereotactic radiation in our population, and I do not believe
any such data have been published in the literature.
As far as using the same assumption in a decision model, one
could do so, but one would not have the results of that assumption.The Journal of Thoracic and CaFor example, in our surgical patients we know which patients ac-
tually had nodal disease, and we do have outcomes in those pa-
tients as having a shorter overall and cause-specific survival.
However, in the SBRT population, we do not have that privilege
because we do not have pathological staging, therefore we cannot
really use that assumption within the decision model within the
construct of the 114 patients from our own center.
Thank you.
DrHiran Fernando (Boston, Mass). That was an excellent pre-
sentation. I am glad that you put in the plug for the Z4099 study, in
which I hope many people here will enroll patients.
I have a couple of questions. In your original report of your
SBRT experience, you had a number of patients with no tissue di-
agnosis, and therefore there were clinically suspicious lung can-
cers that were treated. In this model that you created for your
propensity analysis, was pathological confirmation of lung cancer
a requirement, or did you include patients who did not have a tissue
diagnosis?
Dr Puri. There were 5 or 6 patients in this population who did
not have a tissue diagnosis. Of these patients, several had recur-
rence at some point, and thereforewe eventually had a pathological
diagnosis in these patients. However, of the 57 patients, only
a handful did not have tissue diagnosis.
Dr Fernando. Therefore I would suggest that another factor
that should be included is the need for tissue diagnosis and then
model in the pneumothorax rate that you might see with that and
the need for admission to the hospital that you might need for
the pneumothorax rate and perhaps look at it that way.
Also, in your morbidity outcomes you described the radiation
morbidity. Did you have that morbidity taken out to 3, 6, or 9
months, when you might see the effects of radiation, pneumonitis,
and the effect on pulmonary function?
Dr Puri. Correct. This morbidity was calculated over a period
of 9 months from the time of initial radiation. The 1 major morbid-
ity was a significant pneumonia requiring hospitalization. There
were several minor complications, none of which required hospi-
talization, including rib fractures and a small incidence of pleural
effusions. However, none of these were treated as an inpatient and
did not significantly change the cost curve in this particular anal-
ysis; therefore I did not specifically mention those minor
complications.
Dr David Sugarbaker (Boston, Mass). I enjoyed your article
very much, and I think your whole group is to be congratulated.
I just have one question, and it is really always the looming con-
cern, particularly in a retrospective trial: bias. Presumably, each
one of the patients undergoing SBRT were selected for SBRT
based on a variety of different factors, one of which would be
the presence or absence of N2 disease. One of the indicators to
me that some bias might have played a role here, which I think
we just have to account for, is the higher detectable N2 disease;
it was about 20%, as I saw, for the surgically resected group.
Therefore I wonder whether you could comment a little bit on
bias playing into your results, which is obviously something that
we avoid with an intent-to-treat design.
Thank you very much. I enjoyed your article.
Dr Puri. Thank you. Bias, as Dr Sugarbaker points out, is an in-
trinsic part of any retrospective analysis. First, there is a selection
bias both for the surgical and SBRT arms. We carefully read theserdiovascular Surgery c Volume 143, Number 2 435
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Spatients, and as you saw, 85% of them had undergone a lobectomy.
Therefore as a group of surgeons, we had considered those patients
fit enough to undergo a lobectomy. The majority of patients who
were referred for stereotactic radiation had been seen by our group
and had been denied a lobar resection and thus were discussed at
a multidisciplinary conference and referred for stereotactic radia-
tion. A minority of patients had chosen not to have an operation
and thus underwent stereotactic radiation. All patients, with the ex-
ception of a small handful, probably about 3 or 4 patients in this
57–patient population in the SBRT group, had undergone436 The Journal of Thoracic and Cardiovascular Surgcomputed tomographic and positron emission tomographic scan-
ning to rule out, as effectively as possible, nodal disease in these
patients. Because the study patients were from the 2004–2007
era, we have become even more stringent in trying to rule out path-
ological nodal disease in patients being referred for nonoperative
therapies. With the advent of endobronchial ultrasonography and
with the rather routine use of the video mediastinoscopy and the
availability of endoscopic ultrasonography, I would say in the cur-
rent day and age that we have better pathological mediastinal stag-
ing than from the timeframe in which this study was conducted.ery c February 2012
